Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGON is 42.10M, and at present, short sellers hold a 11.85% of that float. On December 27, 2024, the average trading volume of CGON was 583.05K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CGON) stock’s latest price update
Cg Oncology Inc (NASDAQ: CGON)’s stock price has increased by 2.86 compared to its previous closing price of 28.30. However, the company has seen a 2.32% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-16 that IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, and 700,000 of which were offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share.
CGON’s Market Performance
Cg Oncology Inc (CGON) has seen a 2.32% rise in stock performance for the week, with a -14.26% decline in the past month and a -20.85% plunge in the past quarter. The volatility ratio for the week is 4.70%, and the volatility levels for the past 30 days are at 5.75% for CGON. The simple moving average for the last 20 days is -7.45% for CGON stock, with a simple moving average of -16.95% for the last 200 days.
Analysts’ Opinion of CGON
Many brokerage firms have already submitted their reports for CGON stocks, with UBS repeating the rating for CGON by listing it as a “Buy.” The predicted price for CGON in the upcoming period, according to UBS is $60 based on the research report published on October 24, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see CGON reach a price target of $66. The rating they have provided for CGON stocks is “Outperform” according to the report published on September 23rd, 2024.
ROTH MKM gave a rating of “Buy” to CGON, setting the target price at $65 in the report published on August 28th of the current year.
CGON Trading at -14.69% from the 50-Day Moving Average
After a stumble in the market that brought CGON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.05% of loss for the given period.
Volatility was left at 5.75%, however, over the last 30 days, the volatility rate increased by 4.70%, as shares sank -14.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.75% lower at present.
During the last 5 trading sessions, CGON rose by +2.32%, which changed the moving average for the period of 200-days by -18.39% in comparison to the 20-day moving average, which settled at $31.45. In addition, Cg Oncology Inc saw -21.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGON starting from Song Hong Fang, who sale 700,000 shares at the price of $28.00 back on Dec 16 ’24. After this action, Song Hong Fang now owns 3,003,931 shares of Cg Oncology Inc, valued at $19,600,000 using the latest closing price.
POST LEONARD E, the Director of Cg Oncology Inc, sale 1,000 shares at $28.84 during a trade that took place back on Dec 16 ’24, which means that POST LEONARD E is holding 0 shares at $28,840 based on the most recent closing price.
Stock Fundamentals for CGON
Current profitability levels for the company are sitting at:
- -139.69 for the present operating margin
- 0.98 for the gross margin
The net margin for Cg Oncology Inc stands at -105.78. The total capital return value is set at -0.18.
Currently, EBITDA for the company is -55.43 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 3176.93. The receivables turnover for the company is 4.99for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 35.32.
Conclusion
To sum up, Cg Oncology Inc (CGON) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
